Results 111 to 120 of about 68,398 (251)

A study of antibody secretion from hybridoma cells [PDF]

, 1988
The secretion of monoclonal antibody in both batch and continuous cultures was studied. It was found that when hybridoma cells were continuously cultivated in a simple lab scale fermenter, they secreted less antibody than cells grown in stationary ...
Holland, P.N.
core  

Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia

Biologics: Targets & Therapy, 2015
Sonia Cerquozzi,1 Carolyn Owen2 1Department of Hematology, University of Calgary, 2Department of Hematology, Tom Baker Cancer Centre, Calgary, AB, Canada Abstract: The introduction of targeted therapy against CD20+ with the monoclonal antibody rituximab
Cerquozzi S, Owen C
doaj  

Integrated Engineering of CAR‐T Cells for Solid Tumours

Cell Proliferation, EarlyView.
Solid tumours pose multifactorial barriers including antigen heterogeneity, immunosuppressive microenvironment, and poor T‐cell trafficking, limiting CAR‐T efficacy compared to hematologic malignancies. Integrated engineering strategies are essential, combining logic‐gated receptors for precision, metabolic‐epigenetic reprogramming for resilience, and ...
Chao Yang, Tan Li, Ping He, Zhijie Zhao, Shenglong Li, Liming Wang   +5 more
wiley   +1 more source

Rituximab for the Treatment of Patients with Autoimmune Hepatitis Who are Refractory or Intolerant to Standard Therapy

Canadian Journal of Gastroenterology, 2013
BACKGROUND: Although most patients with autoimmune hepatitis (AIH) respond to treatment with prednisone and/or azathioprine, some patients are intolerant or refractory to standard therapy.
Kelly W Burak, Mark G Swain, Tania Santodomino-Garzon, Samuel S Lee, Stefan J Urbanski, Alexander I Aspinall, Carla S Coffin, Robert P Myers   +7 more
doaj   +1 more source

Ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients

Therapeutics and Clinical Risk Management, 2017
Salma M AlDallal Haematology Laboratory, Amiri Hospital, Kuwait City, Kuwait Abstract: Ofatumumab Arzerra® is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro ...
AlDallal SM
doaj  

Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)

OncoImmunology, 2018
Treatment with monoclonal antibodies has revolutionized clinical medicine, especially in the fields of cancer and immunology. One of the oldest antibodies, which is widely used for the treatment of lymphomas and autoimmune diseases, is the anti-CD20 ...
Shlomo Elias, Shira Kahlon, Rebecca Kotzur, Noah Kaynan, Ofer Mandelboim   +4 more
doaj   +1 more source

Cyclophosphamide is associated with long‐term treatment‐free remission in patients with pemphigus

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objective Pemphigus treatment has seen significant advancements, yet long‐term remission remains a challenge. Comparative data on the long‐term effectiveness of available therapies are limited. We compared 10‐year relapse rates in pemphigus patients treated with azathioprine or cyclophosphamide plus high‐dose IV corticosteroids ...
Bettina Santler, Simon Lüdtke, Lena Dietze, Marie Schiffmann, Dominik Straube, Jan Ehrchen   +5 more
wiley   +1 more source

The different face of skin‐rash induced by brentuximab vedotin

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri, Tullio Brunetti, Serena Rupoli, Gianluca Cafasso, Corrado Zengarini, Staphano Cedirian, Federico Bardazzi, Cosimo Misciali, Michela Starace, Claudio Agostinelli, Gaia Goteri, Erika Morsia   +11 more
wiley   +1 more source

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma [PDF]

, 2018
Izak Faiena,1,2 Amy L Cummings,3 Anna M Crosetti,3 Allan J Pantuck,1,2 Karim Chamie,1,2 Alexandra Drakaki1–3 1Department of Urology, 2Institute of Urologic Oncology, 3Department of Medicine, Division of Hematology and Oncology, David Geffen School
Pantuck AJ, Chamie K, Drakaki A, Crosetti AM, Cummings AL, Faiena I   +5 more
core  

To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Chronic lymphocytic leukemia (CLL) is most frequently diagnosed at early, asymptomatic stages (Rai 0/Binet A), in which a watch‐and‐wait strategy remains the standard of care, based on historical trials demonstrating no overall survival benefit from early treatment.
Enrica Antonia Martino, Santino Caserta, Ernesto Vigna, Giovanna Cutrona, Antonella Bruzzese, Francesco Mendicino, Maria Eugenia Alvaro, Caterina Labanca, Eugenio Lucia, Virginia Olivito, Nicola Amodio, Franco Fais, Antonino Neri, Manlio Ferrarini, Valter Gattei, Fortunato Morabito, Massimo Gentile   +16 more
wiley   +1 more source